- $22.41bn
- $21.91bn
- $606.42m
U.S. RESEARCH ROUNDUP- IQVIA Holdings, Reliance, United Therapeutics
U.S. RESEARCH ROUNDUP-BOK Financial, Sable Offshore, Zscaler
U.S. RESEARCH ROUNDUP-Fortinet, Sailpoint, Zscaler
U.S. RESEARCH ROUNDUP-Home Depot, News, Premier
U.S. RESEARCH ROUNDUP-U.S. RESEARCH ROUNDUP: Air Products, Biogen and JLL
Street View: FDA nod for Insmed's lung disease drug is 'breath of fresh air'
U.S. RESEARCH ROUNDUP-Apollo, Blackstone, Nvidia
Brief: FDA Approves Brinsupri As First Treatment For Non-Cystic Fibrosis Bronchiectasis
US FDA approves Insmed's lung disease drug (updated)
Refile: US FDA approves Insmed's lung disease drug
U.S. RESEARCH ROUNDUP-Bd, Caci International, Caterpillar
Insmed Inc reports results for the quarter ended June 30 - Earnings Summary
Biopharma Insmed's Q2 revenue up 19%, beats estimates
U.S. STOCKS ON THE MOVE-Moderna, Cardinal Health, Adobe
U.S. STOCKS ON THE MOVE-CureVac, Conagra, Oklo
U.S. STOCKS ON THE MOVE-Esty, America's Car-Mart, ImmunoPrecise
Insmed dips after $750 mln stock sale
Brief: Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share
Insmed dips on planned $650 mln stock sale